13F Holdings
中文EN

MRMD MARIMED INC.

Medicinal Chemicals & Botanical Products · OTC · SEC CIK 1522767 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY6.5%
TTM net income YoY14.4%
TTM EPS YoY20.0%
Revenue 3-yr CAGR4.8%
Net income 3-yr CAGR—

Margins

Gross margin35.4%
Operating margin-1.7%
Net margin-9.3%
FCF margin5.5%
EBITDA margin3.6%

Returns

ROE-31.6%
ROA-7.7%
ROIC (approx.)-1.8%
Asset turnover0.83x

Leverage & solvency

Liabilities / assets76.3%
Debt / equity1.95x
Current ratio0.90x
Interest coverage-0.34x

Cash quality & payout

Operating cash flow / net income-0.65x
Accruals ratio-12.7%
Payout ratio—
Capex / revenue0.6%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31FY20232023-12-31FY20222022-12-31FY20212021-12-31
Income statement
Revenue$159.83M$157.71M$148.60M$134.01M$121.46M
Cost of revenue$101.94M$95.10M$82.68M$70.05M$55.20M
Gross profit$57.88M$62.61M$65.92M$63.96M$66.26M
SG&A expense$26.14M$25.62M$22.13M$20.73M$27.56M
Operating income-$2.82M$2.61M$14.38M$20.37M$26.86M
Interest expense$7.50M$6.94M$9.19M$1.69M$2.36M
Pretax income-$10.86M-$4.27M-$6.60M$19.51M$23.82M
Income tax$3.59M$8.16M$9.41M$5.89M$16.19M
Net income-$14.48M-$12.47M-$16.03M$13.47M$7.22M
EBITDA$5.29M$10.52M$19.93M$23.80M$28.96M
EPS (basic)-0.04-0.03-0.040.040.02
EPS (diluted)-0.04-0.03-0.040.040.02
Weighted avg. shares (diluted)390.13M379.15M363.40M380.29M372.40M
Balance sheet
Cash & equivalents$8.88M$7.28M$14.64M$9.74M$29.68M
Short-term investments—$0$88,000$123,000$251,000
Receivables$9.11M$8.74M$7.20M$4.16M$1.67M
Inventory$36.60M$33.49M$25.31M$19.48M$9.77M
Current assets$59.29M$53.51M$51.43M$44.15M$44.61M
PP&E, net$89.39M$94.17M$89.10M$71.64M$62.15M
Goodwill$24.00M$15.81M$11.99M$8.08M$2.07M
Intangibles$17.21M$18.64M$17.01M$14.20M$162,000
Total assets$202.56M$206.99M$196.12M$152.20M$123.20M
Current liabilities$59.07M$50.01M$30.86M$26.49M$27.22M
Long-term debt$76.04M$78.19M———
Total debt$76.04M$78.19M———
Total liabilities$137.83M$129.44M$107.21M$57.17M$49.18M
Shareholders' equity$51.87M$60.30M$70.54M$58.82M$37.86M
Net debt$67.16M$70.91M———
Shares outstanding396.91M381.48M375.13M341.47M334.03M
Cash flow statement
Operating cash flow$7.70M$6.79M$7.91M$7.31M$35.85M
Capital expenditure$1.17M$11.96M$20.13M$12.14M$17.87M
Free cash flow$6.53M-$5.17M-$12.22M-$4.83M$17.98M
Investing cash flow-$1.38M-$17.13M-$25.98M-$26.24M-$16.62M
Financing cash flow-$4.71M$2.98M$22.98M-$1.01M$7.45M
Depreciation & amortization$8.11M$7.91M$5.55M$3.43M$2.10M
Stock-based compensation$1.86M$1.05M$1.02M$6.34M—

Free plan shows the latest 5 periods; Pro shows all 15 🔒

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.